Chinese burn: new blacklists to expose healthcare company misbehaviour
This article was originally published in Scrip
Pharmaceutical companies that value their reputation in China will soon need to tread more carefully when it comes to keeping in line with local drug and device laws. From 1 October a new blacklist will publically expose misbehaving companies and their misdemeanours for patients and healthcare professionals to see.
You may also be interested in...
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
Brazil’s pharmaceutical industry has welcomed the election of medicines regulator ANVISA to the management committee of the International Council for Harmonization.